Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: glipizide

« Back to Dashboard

Glipizide is the generic ingredient in five branded drugs marketed by Par Pharm, Watson Labs, Pfizer, Accord Hlthcare, Apotex, Barr Labs Inc, Ivax Sub Teva Pharms, Mylan, Sandoz, Sun Pharm Inds Inc, Teva, Vintage Pharms Llc, Corepharma, Heritage Pharms Inc, Teva Pharms, Zydus Pharms Usa Inc, and Bristol Myers Squibb, and is included in twenty-four NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for glipizide. Eight suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: glipizide

Tradenames:5
Patents:2
Applicants:17
NDAs:24
Drug Master File Entries: see list17
Suppliers: see list8
Therapeutic Class:Blood Glucose Regulators

Pharmacology for Ingredient: glipizide

Ingredient-typeSulfonylurea Compounds
Drug ClassSulfonylurea

Tentative approvals for GLIPIZIDE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET, EXTENDED RELEASE;ORAL5MG
<disabled><disabled>TABLET, EXTENDED RELEASE;ORAL10MG
<disabled><disabled>TABLET, EXTENDED RELEASE;ORAL2.5MG

Clinical Trials for: glipizide

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)
Status: Completed Condition: Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting
Status: Completed Condition: Healthy

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting
Status: Completed Condition: Healthy

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
Status: Completed Condition: Diabetes Mellitus, Type 2; End-Stage Kidney Disease

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
Status: Completed Condition: Type 2 Diabetes Mellitus

Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
Status: Completed Condition: Diabetes Mellitus

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
GLIPIZIDE
glipizide
TABLET, EXTENDED RELEASE;ORAL076467Nov 7, 2003RXNo<disabled><disabled>
Pfizer
GLUCOTROL
glipizide
TABLET;ORAL017783May 8, 1984RXNo<disabled><disabled>
Mylan
GLIPIZIDE AND METFORMIN HYDROCHLORIDE
glipizide; metformin hydrochloride
TABLET;ORAL078083Apr 12, 2007RXNo<disabled><disabled>
Teva Pharms
GLIPIZIDE AND METFORMIN HYDROCHLORIDE
glipizide; metformin hydrochloride
TABLET;ORAL077270Oct 28, 2005RXYes<disabled><disabled>
Apotex
GLIPIZIDE
glipizide
TABLET;ORAL075795Jun 13, 2001RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc